Company intelligence / Profile preview
Telios Pharma
Redwood City, California, United Statesteliospharma.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Telios Pharma recently announced successful Phase 2 results for TL-925, a first-in-class topical BTK inhibitor for dry eye disease. The study showed clinically meaningful and statistically significant improvements across multiple signs and symptoms in patients with moderate to severe dry eye disease when dosed twice daily for 28 days. The treatment demonstrated rapid onset of efficacy across multiple ocular regions with favorable safety and tolerability profiles.[2]
- Therapeutic areas
- EndocrinologyHematologyOtherCardiovascularOphthalmology
- Modalities
- Small molecule drugsBTK inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Kartos Therapeutics, Inc.
Beyond the preview
Go deeper on Telios Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telios Pharma.